In the future, we plan to narrow our focus to specific pathways using a targeted metabolomics approach to improve our biological understanding in both clinical and preclinical research, especially before intensely pursuing individual metabolites as putative driving factors of skeletal muscle dysfunction in FKRP-related dystroglycanopathies. The gene discussed is FKRP; the disease is neuromuscular disease caused by qualitative or quantitative defects of alpha-dystroglycan.